OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGNGet Rating) in a report issued on Friday. The firm set a “sell” rating on the medical research company’s stock.

OPGN has been the subject of a number of other reports. HC Wainwright reaffirmed a “buy” rating and set a $3.00 target price on shares of OpGen in a research report on Friday, June 10th. Alliance Global Partners downgraded OpGen to a “neutral” rating in a report on Tuesday, July 19th.

OpGen Trading Up 5.3 %

Shares of NASDAQ OPGN opened at $0.62 on Friday. The company has a quick ratio of 1.69, a current ratio of 1.76 and a debt-to-equity ratio of 0.23. The business has a fifty day simple moving average of $0.56 and a two-hundred day simple moving average of $0.66. The firm has a market cap of $28.68 million, a PE ratio of -0.72 and a beta of -0.37. OpGen has a twelve month low of $0.31 and a twelve month high of $3.72.

OpGen (NASDAQ:OPGNGet Rating) last issued its earnings results on Thursday, May 12th. The medical research company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The business had revenue of $0.47 million during the quarter, compared to analyst estimates of $1.05 million. OpGen had a negative return on equity of 72.67% and a negative net margin of 680.36%. Analysts expect that OpGen will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in OpGen stock. Arete Wealth Advisors LLC grew its stake in OpGen, Inc. (NASDAQ:OPGNGet Rating) by 70.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,000 shares of the medical research company’s stock after acquiring an additional 35,000 shares during the quarter. Arete Wealth Advisors LLC owned about 0.18% of OpGen worth $64,000 at the end of the most recent quarter. 10.95% of the stock is currently owned by institutional investors and hedge funds.

About OpGen

(Get Rating)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.